Table 1 Patient characteristics and antifungal prophylaxis regimen
Characteristic | PAP (N = 818) | SAP (N = 88) | Non-antifungal prophylaxis (n = 147) |
|---|---|---|---|
Age, mean (range/%)/case | 28.5 (1–63) | 32.2 2–58) | 29.6 (4–61) |
 0–6 | 33 (4 %) | 3 (3.4 %) | 4 (2.7 %) |
 >6–16 | 129 (15.8 %) | 10 (11.4 %) | 20 (13.6 %) |
 >16–40 | 488 (59.7 %) | 49 (55.7 %) | 85 (57.8 %) |
 >40–65 | 168 (20.5 %) | 26 (29.5 %) | 38 (25.9 %) |
Gender | |||
 Male | 505 (61.7 %) | 51 (58.0 %) | 87 (59.2 %) |
 Female | 313 (38.3 %) | 37 (42.0 %) | 60 (40.8 %) |
E-COG | |||
 0 | 227 (27.8 %) | 18 (20.5 %) | 48 (32.7 %) |
 1 | 438 (53.5 %) | 54 (61.4 %) | 74 (50.3 %) |
 2 | 89 (10.9 %) | 11 (12.5 %) | 17 (11.6 %) |
 3 | 51 (6.2 %) | 5 (5.7 %) | 7 (4.8 %) |
 4 | 13 (1.6 %) | – | 1 (0.7 %) |
Underlying disease | |||
 Acute myeloid leukemia | 289 (35.3 %) | 44 (50.0 %) | 43 (29.3 %) |
 Acute lymphocytic leukemia | 241 (29.5 %) | 32 (36.4 %) | 37 (25.2 %) |
 Chronic myeloid leukemia | 100 (12.2 %) | 3 (3.4 %) | 23 (15.6 %) |
 Aplastic anemia | 69 (8.4 %) | – | 13 (8.8 %) |
 Myelodysplastic syndrome | 62 (7.6 %) | 2 (2.3 %) | 16 (10.9 %) |
 Non-Hodgkin’s lymphoma | 23 (2.8 %) | 4 (4.5 %) | 4 (2.7 %) |
 Chronic lymphocytic leukemia | 4 (0.5 %) | – | – |
 Multiple myeloma | 2 (0.2 %) | – | 1 (0.7 %) |
 Hodgkin’s disease | 2 (0.2 %) | – | 3 (2.0 %) |
 Myeloprolififerative neoplasms | 2 (0.2 %) | – | – |
 Solid tumor | 1 (0.1 %) | – | – |
 Hereditary and metabolic disorders | 9 (1.1 %) | – | – |
 Paroxysmal nocturnal hemoglobinuria | 1 (0.1 %) | – | 1 (0.7 %) |
 Othersa | 13 (1.6 %) | 3 (3.4 %) | 6 (4.1 %) |
Transplantation type | |||
 HLA-matched related (sibling) | 335 (41.0 %) | 35 (39.8 %) | 77 (52.4 %) |
 Haploidentical | 269 (32.9 %) | 26 (29.5 %) | 35 (23.8 %) |
 Unrelated | 213 (26.0 %) | 27 (30.7 %) | 35 (23.8 %) |
Source of stem cells | |||
 PB | 417 (51.0 %) | 67 (76.1 %) | 105 (71.4 %) |
 BM + PB | 348 (42.5 %) | 19 (21.6 %) | 20 (13.6 %) |
 BM | 33 (4.0 %) | – | 7 (4.8 %) |
 CB | 15 (1.8 %) | 1 (1.1 %) | 3 (2.0 %) |
 BM + CB | 3 (0.4 %) | – | – |
 BM + PB + CB | 2 (0.2 %) | 1 (1.1 %) | 8 (5.4 %) |
Conditioning regimen | |||
 Myeloablative | |||
  Yes | 729 (89.1 %) | 83 (94.3 %) | 124 (84.4 %) |
  No | 89 (10.9 %) | 5 (5.7 %) | 23 (15.6 %) |
 Total body radiotherapy | |||
  Yes | 122 (14.9 %) | 23 (26.1 %) | 13 (8.8 %) |
  No | 696 (85.1 %) | 65 (73.9 %) | 134 (91.2 %) |
Antithymocyte globulin | |||
 Yes | 516 (63.1 %) | 52 (59.1 %) | 64 (43.5 %) |
 No | 302 (36.9 %) | 36 (40.9 %) | 83 (56.5 %) |
Concomitant disease | 137 (16.7Â %) | 22 (25.0Â %) | 23 (15.6Â %) |
 Cardiovascular disease | 24 (2.9 %) | 2 (2.3 %) | 4 (2.7 %) |
 Diabetes | 24 (2.9 %) | 2 (2.3 %) | 6 (4.1 %) |
 Viral hepatitis | 22 (2.7 %) | 9 (10.2 %) | 4 (2.7 %) |
 CMV infection | 1 (0.1 %) | 2 (2.3 %) | 1 (0.7 %) |
 Tuberculosis | 14 (1.7 %) | 3 (3.4 %) | 2 (1.4 %) |
 Autoimmune diseases | 9 (1.1 %) | 1 (1.1 %) | – |
 Othersb | 61 (7.5 %) | 5 (5.7 %) | 8 (5.4 %) |
aGVHD | Â | Â | Â |
 I–II aGVHD | 257 (31.4 %) | 27 (30.7 %) | 40 (27.2 %) |
 III–IV aGVHD | 57 (7.0 %) | 7 (8.0 %) | 15 (10.2 %) |
cGVHD | |||
 Limited | 57 (7.0 %) | 9 (10.3 %) | 10 (6.85) |
 Extensive | 24 (2.9 %) | 2 (2.3 %) | 4 (2.7 %) |
Drugs for IFD prophylaxis | |||
 Single drug | 667 (81.5 %) | 69 (78.4 %) | – |
  Fluconazole | 429 (64.3 %) | 8 (11.6 %) | – |
  Itraconazole | 103 (15.4 %) | 17 (24.6 %) | – |
  Voriconazole | 71 (10.6 %) | 32 (46.4 %) | – |
  Caspofungin | 4 (0.6 %) | 6 (8.7 %) | – |
  Amphotericin B | 2 (0.3 %) | 1 (1.4 %) | – |
 Drug combination | 151 (18.5 %) | 19 (21.6 %) | – |
Route of administration | |||
 Oral | 466 (57.0 %) | 29 (33.0 %) | – |
 Intravenous | 214 (26.2 %) | 37 (42.0 %) | – |
 Oral + intravenous | 138 (16.9 %) | 22 (25.0 %) | – |
Time of prophylaxis before HSCT mean (SD), days | 10.8 (6.57) | 12.0 (6.43) | – |